HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TAK-637. Takeda.

Abstract
Abbott and Takeda are developing TAK-637, an orally active NK1 antagonist, for the potential treatment of urinary incontinence, depression, irritable bowel syndrome and pollakiuria. By November 1999, it was in phase II trials in Europe and phase I in Japan and the US for urinary incontinence [348496], [350686]. By October 2000, phase II trials had been initiated in the US for urinary incontinence, depression and IBS [381167], [386950], [419868], and in May 2001, these were scheduled to finish in 2002 [412024].
AuthorsJ B Furness
JournalCurrent opinion in investigational drugs (London, England : 2000) (Curr Opin Investig Drugs) Vol. 2 Issue 10 Pg. 1437-40 (Oct 2001) ISSN: 1472-4472 [Print] England
PMID11890361 (Publication Type: Journal Article, Review)
Chemical References
  • Naphthyridines
  • Neurokinin-1 Receptor Antagonists
  • TAK 637
Topics
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Colonic Diseases, Functional (drug therapy)
  • Depression (drug therapy)
  • Humans
  • Naphthyridines (pharmacology, therapeutic use)
  • Neurokinin-1 Receptor Antagonists
  • Structure-Activity Relationship
  • Urinary Incontinence (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: